Clinical trials: Neurobehavioral Manifestation
Prader-Willi Syndrome, Hyperphagia
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).
- Trial name
- ZEPHYR (NCT03790865)
- Testing
- Livoletide
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 158 people
- Sponsor
- Millendo Therapeutics SAS
Pain, Postoperative, Pediatrics
An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients
The purpose of this study is to evaluate the safety and clinical utility of fentanyl HCl 40 mcg system for the management of postoperative pain in pediatric inpatients.
- Trial name
- NCT00666393
- Testing
- fentanyl iontophoretic transdermal system (40mcg)
- Sponsor
- Alza Corporation, DE, USA
Terminal Illness, End-of-Life Care
Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence
Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power…
- Conditions
- Terminal Illness, End-of-Life Care, Death, Brain Death
- Trial name
- NeuroCogPresv (NCT07477028)
- Volunteers
- 20 people
- Sponsor
- Noah Tech, Corp.
Arrythmia, Syncope
Arrhythmia Identification in Syncope Patients: ePatch® Versus 24h Holter
This study is a Multi-center, prospective, randomized, unblinded, two-arm study to assess if 7-days of cardiac monitoring using the ePatch Holter results in identification of more clinically actionable arrythmia for patients with…
- Trial name
- NCT06310707
- Testing
- ePatch ® Extended Wear Holter (EWH)
- Where
- 2 sites in France, Germany
- Volunteers
- 55 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Trisomy 13, Trisomy 18
High Risk Multiple Gestation Study
The objectives of the clinical study are to demonstrate the accuracy of our proprietary algorithm method to determine the genetic health of the developing fetuses in a multiple gestation pregnancy from a maternal blood sample.
- Conditions
- Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
- Trial name
- NCT02278874
- Where
- 4 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Major Depressive Disorder, Anhedonia
PD, PK, and Safety of ALTO-203 in Patients With MDD
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period.
- Trial name
- NCT06391593
- Testing
- ALTO-203 25 μg, ALTO-203 75 μg
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alto Neuroscience
Learning Disabilities, Child
Development, Validation and Testing of an Education Program for Identification of Learning Disabilities Among School Children by Primary School Teachers in Qatar
Aim The aim of this study to develop, validate and test an education program for identification of learning disabilities among school children by Primary school teachers in Qatar Objectives 1.
- Trial name
- LD - Learning (NCT06642974)
- Testing
- Education module on learning disabilities, pamphlet on learning disability
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Memory Loss
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
- Trial name
- NCT00293176
- Testing
- Donepezil Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 821 people
- Sponsor
- Eisai Inc.
Broca Aphasia
Speech Hero Home Therapy for Aphasia
The investigators will run an at-home usability study of a newly developed speech therapy app called Speech Hero with 10 individuals with Broca's aphasia in the chronic stage of stroke.
- Trial name
- NCT04471935
- Testing
- At home Speech Hero therapy app
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Opioid-use Disorder, Opioid Misuse
Comparing a Patient Self-Assessment Software to Treatment as Usual in Opioid Prescriber and Patient Opioid Outcomes
The Care Continuity Program (CCP), a product of Sure Med Compliance, is a novel, online patient self-assessment used by prescribers of opioids to better identify patient risk factors and therapy benefit.
- Conditions
- Opioid-use Disorder, Opioid Misuse, Opioid Use, Chronic Pain
- Trial name
- NCT04945525
- Testing
- Care Continuity Program
- Where
- United States
- Volunteers
- 1,840 people
- Sponsor
- Sure Med Compliance
Bipolar Disorder
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder.
- Trial name
- NCT00107926
- Testing
- Licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 343 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder, Reading Disorder
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with…
- Trial name
- NCT00191906
- Testing
- Atomoxetine Hydrochloride
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
- Trial name
- NCT06194799
- Testing
- ACP-204
- Where
- 78 sites in United States, Brazil and 10 more
- Volunteers
- 752 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Down Syndrome
Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30
To evaluate the suitability (i.e. number of tests completed and number of participants completing the tests, variance estimate of baseline and of the change from baseline values) of neurocognitive tests and functioning scales in…
- Trial name
- NCT02431117
- Where
- 7 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Chugai Pharmaceutical
Pain, Chronic
Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
The purpose of this study is to evaluate the efficacy and safety of Canadá association in the treatment of chronic pain
- Trial name
- CANADÁ (NCT05125978)
- Testing
- Canadá, Dipyrone, Tramadol hydrochloride
- Sponsor
- EMS
Disorders of Consciousness, Vegetative State
AI-Assisted Precision Hyperbaric Oxygen Therapy Based on Dynamic BIS-EEG Feedback for Patients With Disorders of Consciousness
Disorders of consciousness (DoC) are severe neurological conditions characterized by impaired awareness and reduced interaction with the environment.
- Conditions
- Disorders of Consciousness, Vegetative State, Minimally Conscious State
- Trial name
- AI-HBOT-DoC (NCT07855848)
- Testing
- AI-Assisted Personalized Hyperbaric Oxygen Therapy, Conventional Hyperbaric Oxygen Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.